Syros Pharmaceuticals (SYRS) Institutional Ownership $0.0016 +0.00 (+45.45%) As of 08/28/2025 03:26 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Syros Pharmaceuticals (NASDAQ:SYRS)CurrentInstitutional OwnershipPercentage91.47%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$358.66KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$428.20K Get SYRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Syros Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data SYRS Institutional Buying and Selling by Quarter Syros Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 Two Sigma Securities LLC107,742$25K0.0%N/A0.402% 12/13/2024 Exome Asset Management LLC298,575$642K0.4%+87.6%1.113% 11/14/2024 Walleye Capital LLC86,641$186K0.0%-69.7%0.323% 11/5/2024 GSA Capital Partners LLP15,905$34K0.0%N/A0.059% 8/9/2024 Renaissance Technologies LLC117,435$606K0.0%-2.0%0.438% 8/6/2024 Certuity LLC21,202$109K0.0%N/A0.079% 8/6/2024 Acadian Asset Management LLC34,578$178K0.0%+101.5%0.129% 7/18/2024 Assenagon Asset Management S.A.15,873$82K0.0%-90.7%0.059% 5/29/2024 Opaleye Management Inc.787,545$4.21M0.9%+119.1%2.947% 5/20/2024 Virtu Financial LLC12,030$64K0.0%N/A0.045% Get the Latest News and Ratings for SYRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/16/2024 Kennedy Capital Management LLC404,914$2.17M0.0%N/A1.515% 5/10/2024 Acadian Asset Management LLC17,162$91K0.0%N/A0.064% 5/10/2024 Vanguard Group Inc.928,046$4.97M0.0%+21.3%3.472% 4/24/2024 Assenagon Asset Management S.A.169,999$909K0.0%+576.5%0.636% 2/15/2024 Opaleye Management Inc.359,370$2.80M0.7%N/A1.706% 2/15/2024 Flagship Pioneering Inc.1,293,848$10.08M0.8%+30.2%6.141% 2/14/2024 Avidity Partners Management LP1,673,538$13.04M0.5%+5.8%7.943% 2/13/2024 Bain Capital Life Sciences Investors LLC2,749,808$21.42M2.1%+29.4%13.051% 11/14/2023 Avidity Partners Management LP1,581,142$6.25M0.3%+8.0%7.635% 11/13/2023CHI Advisors LLC1,299,359$5.12M1.5%+69.3%6.274% 11/6/2023 Assenagon Asset Management S.A.25,130$99K0.0%+142.2%0.121% 10/19/2023 Clarius Group LLC18,620$74K0.0%N/A0.090% 8/14/2023 Shay Capital LLC26,426$83K0.0%+87.3%0.128% 8/11/2023 ExodusPoint Capital Management LP118,398$373K0.0%-2.6%0.572% 5/16/2023 Ally Bridge Group NY LLC249,126$665K0.9%-71.3%1.210% 5/11/2023CHI Advisors LLC767,445$2.05M0.5%N/A3.760% 4/18/2023 Assenagon Asset Management S.A.10,376$28K0.0%N/A0.051% 2/9/2023 Denali Advisors LLC7,700$28K0.0%N/A0.038% 11/15/2022 Flagship Pioneering Inc.993,848$6.40M0.3%-66.2%15.775% 11/15/2022 Bain Capital Life Sciences Investors LLC1,082,404$6.97M0.8%-82.7%17.181% 11/9/2022 Edmond DE Rothschild Holding S.A.4,382$28K0.0%N/A0.070% 10/24/2022 Clarius Group LLC19,347$125K0.0%-90.0%0.307% 10/13/2022 LGT Capital Partners LTD.55,000$354K0.0%-90.0%0.873% 8/11/2022 Artal Group S.A.4,000,000$3.85M0.2%+14.3%6.367% 8/10/2022 Clarius Group LLC193,483$186K0.0%N/A0.308% 7/19/2022Sawtooth Solutions LLC42,286$41K0.0%+76.5%0.067% 7/13/2022 LGT Capital Partners LTD.550,000$529K0.0%+10.0%0.876% 7/13/2022 Private Advisor Group LLC51,437$50K0.0%+112.9%0.082% 5/16/2022 Ally Bridge Group NY LLC3,364,895$4.00M3.0%-4.9%5.420% 5/12/2022 Artal Group S.A.3,500,000$4.17M0.2%+16.7%5.638% The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad)Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.This little-known company holds nearly 100 patents and trades for around $75/12/2022 Connor Clark & Lunn Investment Management Ltd.137,156$163K0.0%+15.6%0.221% 5/11/2022ACT Capital Management LLC35,000$42K0.0%+62.8%0.056% 5/11/2022 GSA Capital Partners LLP372,208$443K0.1%+53.7%0.600% 2/15/2022 Adage Capital Partners GP L.L.C.1,900,000$6.19M0.0%+5.6%3.067% 2/14/2022 Altium Capital Management LP1,160,000$3.78M1.0%-8.8%1.873% 2/14/2022 GSA Capital Partners LLP242,132$789K0.1%+119.4%0.391% 2/14/2022 Ally Bridge Group NY LLC3,539,895$11.54M4.0%+2.9%5.714% 2/11/2022 Ensign Peak Advisors Inc45,000$147K0.0%-55.0%0.073% 2/10/2022 Connor Clark & Lunn Investment Management Ltd.118,632$387K0.0%+14.8%0.192% 2/7/2022 SG Americas Securities LLC12,012$39K0.0%-61.4%0.019% 2/3/2022ACT Capital Management LLC21,500$70K0.1%-59.0%0.035% 1/14/2022 LGT Capital Partners LTD.500,000$1.63M0.0%+1,052.4%0.807% 11/17/2021 Altium Capital Management LP1,272,412$5.69M1.3%+18.2%2.054% 11/16/2021 Two Sigma Advisers LP172,700$772K0.0%-32.6%0.279% 11/16/2021 Two Sigma Investments LP91,278$408K0.0%-24.2%0.147% 11/16/2021 Metropolitan Life Insurance Co NY16,415$73K0.0%N/A0.026% 11/15/2021 Point72 Hong Kong Ltd7,062$32K0.0%+168.8%0.011% 11/15/2021 Cubist Systematic Strategies LLC86,990$389K0.0%-66.3%0.140% 11/15/2021 Marshall Wace LLP183,451$820K0.0%-38.1%0.296% 11/15/2021 Franklin Resources Inc.64,000$286K0.0%N/A0.103% 11/15/2021 GSA Capital Partners LLP110,337$493K0.1%-21.7%0.178% 11/12/2021 Trexquant Investment LP30,162$135K0.0%-10.4%0.049% 11/12/2021 Geode Capital Management LLC857,646$3.83M0.0%-11.3%1.384% 11/12/2021 Artal Group S.A.2,000,000$8.94M0.2%+17.6%3.229% 11/12/2021 Connor Clark & Lunn Investment Management Ltd.103,307$462K0.0%+35.8%0.167% 11/10/2021 Goldman Sachs Group Inc.490,501$2.19M0.0%-2.1%0.792% 11/10/2021 Citigroup Inc.9,702$43K0.0%+49.5%0.016% 11/9/2021 Barclays PLC44,863$200K0.0%-23.7%0.072% 11/9/2021BlackRock Inc.4,353,672$19.46M0.0%-2.5%7.030% 11/9/2021 Ieq Capital LLC27,800$124K0.0%N/A0.045% 11/8/2021 Summit Global Investments31,800$142K0.0%N/A0.051% 11/8/2021 State Board of Administration of Florida Retirement System78,535$351K0.0%+233.0%0.127% 11/8/2021 Russell Investments Group Ltd.10,289$45K0.0%-49.4%0.017% 11/8/2021 Los Angeles Capital Management LLC258,938$1.16M0.0%-4.6%0.418% 11/4/2021 Deutsche Bank AG59,973$268K0.0%+65.9%0.097% 11/1/2021 SG Americas Securities LLC31,096$139K0.0%N/A0.050% 10/19/2021 Assenagon Asset Management S.A.87,073$389K0.0%-24.8%0.141% 10/13/2021 LGT Capital Partners LTD.43,388$194K0.0%N/A0.070% 9/3/2021Parametric Portfolio Associates LLC19,110$104K0.0%N/A0.031% 8/25/2021 Marshall Wace LLP296,405$1.62M0.0%N/A0.479% 8/17/2021 Millennium Management LLC557,713$3.04M0.0%+230.4%0.901% 8/17/2021Caas Capital Management LP13,905$76K0.0%N/A0.022% 8/16/2021 PDT Partners LLC116,801$637K0.0%-20.8%0.189% 8/16/2021 Cubist Systematic Strategies LLC257,997$1.41M0.0%+891.3%0.417% 8/16/2021 Redmile Group LLC38,912$212K0.0%-81.7%0.063% 8/16/2021 California State Teachers Retirement System79,478$433K0.0%+11.7%0.128% 8/16/2021 Charles Schwab Investment Management Inc.391,798$2.14M0.0%+7.9%0.633% 8/16/2021 State Street Corp999,254$5.45M0.0%+25.6%1.613% 8/16/2021Nuveen Asset Management LLC180,514$984K0.0%+23.1%0.291% 8/16/2021 Omega Fund Management LLC2,274,831$12.40M2.1%+45.6%3.673% This is my Christian duty (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code8/16/2021 Goldman Sachs Group Inc.501,221$2.73M0.0%-21.3%0.809% 8/16/2021 Marshall Wace LLP296,405$1.62M0.0%N/A0.479% 8/13/2021 Northern Trust Corp554,422$3.02M0.0%+6.6%0.895% 8/13/2021 Altium Capital Management LP1,076,942$5.87M1.4%+750.0%1.739% 8/13/2021 LPL Financial LLC38,090$208K0.0%+97.1%0.062% 8/13/2021 Qube Research & Technologies Ltd78,774$429K0.0%+115.9%0.127% 8/13/2021 Geode Capital Management LLC966,448$5.27M0.0%+16.0%1.561% 8/13/2021 Vanguard Group Inc.2,775,576$15.13M0.0%+1.6%4.482% 8/13/2021 FMR LLC9,047,965$49.31M0.0%+0.4%14.610% 8/13/2021 ProShare Advisors LLC26,050$142K0.0%+23.3%0.042% (Data available from 1/1/2016 forward) SYRS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SYRS shares? During the previous two years, 17 institutional investors and hedge funds held shares of Syros Pharmaceuticals. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($21.42M), Avidity Partners Management LP ($13.04M), Flagship Pioneering Inc. ($10.08M), CHI Advisors LLC ($5.12M), Vanguard Group Inc. ($4.97M), Opaleye Management Inc. ($4.21M), and Kennedy Capital Management LLC ($2.17M).Learn more on Syros Pharmaceuticals' institutional investors. What percentage of Syros Pharmaceuticals' stock is owned by institutional investors? 91.47% of Syros Pharmaceuticals' stock is owned by institutional investors. Learn more on SYRS's institutional investor holdings. Which institutional investors have been buying Syros Pharmaceuticals' stock? Of the 15 institutional investors that purchased Syros Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Opaleye Management Inc. ($787.55K), Bain Capital Life Sciences Investors LLC ($625.11K), CHI Advisors LLC ($531.91K), Kennedy Capital Management LLC ($404.91K), Flagship Pioneering Inc. ($300K), Avidity Partners Management LP ($209.50K), and Vanguard Group Inc. ($163.23K). How much institutional buying is happening at Syros Pharmaceuticals? Institutional investors have bought a total of 263,047 shares in the last 24 months. This purchase volume represents approximately $358.66K in transactions. Which of Syros Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Syros Pharmaceuticals stock in the last 24 months: Walleye Capital LLC ($199.16K). How much institutional selling is happening at Syros Pharmaceuticals? Institutional investors have sold a total of 199,162 shares in the last 24 months. This volume of shares sold represents approximately $428.20K in transactions. Related Companies NCNA Major Shareholders VRPX Major Shareholders This page (NASDAQ:SYRS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access